A João, P Serrano, E Bártolo, A Neves, F Menezes Brandão

Idioma: Portugués
Referencias bibliográficas: 11
Paginas: 154-160
Archivo PDF: 151.21 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Glenner GG. Amyloid deposits and amyloidosis. The B-fibrilloses. N Engl J Med 1980; 302: 1283-92.

2. Breathnach SM. Amyloid and amyloidosis. J Am Acad Dermatol 1988; 18: 1-16.

3. Falk RH, Comenzo RL, Skinner M. The Systemic Amyloidosis. N Engl J Med 1997; 25: 898-908.

4. Kois JM, Sexton FM, Lookingbill. Cutaneous Manifestations of Multiple Myeloma. Arch Dermatol 1991; 127: 69-74.

5. Gutiérrez JV, Fernández MM, Sambucety PS, Valiente JS, Prieto MA. Med Cutan Iber Lat Am 2004; 32: 211-4.

6. Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chains of immunoglobulins: preferential association of the V l VI subgroup of human light chains with amyloidosis AL (l). J Clin Invest 1982; 70: 453- 60.

7. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665-83.

8. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59.

9. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-7.

10. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for treatment of AL amyloidosis: one year follow-up in five patients. Blood 1996; 88: 2801-6.

11. Dubrey SW, Mendes L, Skinner M, Falk RH. Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med 1996; 125: 481-4.